治疗耐药性重度抑郁症的胺:双盲主动控制交叉研究
Paul Glue1, Shona Neehoff1, Ben Beaglehole2
1Department of Psychological Medicine, University of Otago, Dunedin, New Zealand.
Journal of psychopharmacology (Oxford, England)
|January 31, 2024
概括
胺迅速减少了治疗耐药性抑郁症 (TRD) 患者的抑郁和焦虑. 大多数患者对氨酸有反应,氨酸是安全的,耐受性很好,与对照组不同.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 胺,一种N-甲基-D-酸对手,在治疗耐药性抑郁症 (TRD) 中表现出快速的抗抑郁作用.
- 了解胺的疗效和安全性对于TRD管理至关重要.
研究的目的:
- 为了评估TRD患者对胺的情绪,安全性和耐受性.
- 为了比较基他胺与精神活性对照药 (芬太尼) 的作用.
- 探索与情绪反应相关的EEG生物标志物.
主要方法:
- 双盲,主动控制,随机交叉研究.
- 25 TRD患者每周接受肌肉内胺 (0.5和1毫克/公斤) 或芬太尼 (50毫克) 的治疗.
- 评估了情绪评分,安全性和耐受性.
主要成果:
- 胺可在1小时内显著降低抑郁和焦虑评级,持续长达7天.
- 56%的患者根据HADS抑郁症对胺反应,而72%的患者根据HADS焦虑反应.
- 芬太尼显示出极少的抗抑郁或抗焦虑作用.
结论:
- 胺是有效的和耐受良好的治疗抑郁和焦虑症状在TRD.
- 这些发现支持胺在治疗耐药抑郁症的管理中的作用.
- 对EEG生物标志物的进一步研究可能会改进胺治疗策略.
相关概念视频
01:30Electroconvulsive Therapy
41
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
41
01:23Antidepressant Drugs: MAOIs and Other Agents
234
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
234